The Pharmacy Times® HIV Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of HIV, a virus that attacks the body's immune system and, if left untreated, can lead to AIDS.
April 26th 2024
The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacy Technician Credi...
2.0 Credits / HIV/AIDS
View More
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacist Credit)
2.0 Credits / HIV/AIDS
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
New Research Provides Information for First Trial of CRISPR-Based HIV Therapy in Humans
September 22nd 2021Khalili and his colleagues have completed preclinical studies that have shown that EBT-101 can effectively excise HIV proviral DNA from the genomes of different cells and tissues, including HIV-infected human cells and cells and tissues of humanized mice.
Read More
Multimorbidity, health-related quality of life, and stigma and discrimination continue to be major issues for people living with HIV, including those who have achieved viral suppression, according to a consensus statement from a multidisciplinary panel of HIV experts published in Nature Communications.
Read More
Clinical Trial Shows Safety, Efficacy of Monthly Oral Islatravir for HIV-1 Prevention
August 2nd 2021The investigators noted that the levels of islatravir in peripheral blood mononuclear cells remained above the efficacy pharmacokinetics threshold for PrEP for both doses studied (60 mg and 120 mg) for 8 weeks following the last study dose.
Read More
Biktarvy Demonstrates Efficacy, Viral Suppression in Treatment-Naïve Adults With HIV
July 28th 2021A pooled analysis of a 48-week open-label extension of a pair of phase 3 studies found that 99% of patients with HIV who initiated treatment using bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets maintained an undetectable viral load through 4 years of follow-up.
Read More
Because viral clearance is compromised if HIV is allowed to replicate for an extended period of time—resulting in extensive damage to the immune system—controlling HIV with antiretroviral therapy may be critical to preventing this type of viral evolution in SARS-CoV-2 in patients with advanced HIV.
Read More
Study: People Living with HIV/AIDS at Significantly Higher Risk of Suicide
July 8th 2021Despite significant medical advancements related to HIV treatment and quality of life, the risk of suicide in patients is high and health care providers should prioritize mental health screenings in this population.
Read More